Hyaluronic acid-coated, prodrug-based nanostructured lipid carriers for enhanced pancreatic cancer therapy
Zhihe Lu, Jingrong Su, Zhengrong Li, Yuzhu Zhan, Decai YeDOI 10.1080/03639045.2016.1226337
Summary
Gemcitabine (GEM) monotherapy for pancreatic cancer has poor tumor specificity, short circulation half-life, and drug resistance. Baicalein (BCL) can downregulate Bcl-2/Mcl-1 and sensitize tumor cells, but it has poor solubility, low bioavailability, and rapid metabolism. A targeted co-delivery system was needed to combine GEM and BCL, improve pharmacokinetics, and enhance antitumor efficacy. HA-GEM-BCL NLCs: size 131.4 ± 3.9 nm, PDI 0.12 ± 0.03, zeta potential −25.1 ± 1.9 mV, GEM EE 85.1 ± 2.3%, BCL EE 82.9 ± 2.4%. - NLCs were stable over 1 month; release was faster at pH 5.0 than pH 7.4. - Cellular uptake.
Keywords
Purpose: Gemcitabine (GEM) monotherapy for pancreatic cancer has poor tumor specificity, short circulation half-life, and drug resistance. Baicalein (BCL) can downregulate Bcl-2/Mcl-1 and sensitize tumor cells, but it has poor solubility, low bioavailability, and rapid metabolism. A targeted co-delivery system was needed to combine GEM and BCL, improve pharmacokinetics, and enhance antitumor efficacy.
Hypothesis: If GEM and BCL are converted into lipid/HA-based prodrugs and co-loaded into hyaluronic acid-coated nanostructured lipid carriers (HA-GEM-BCL NLCs), then the system will target HA receptor-overexpressing pancreatic cancer cells, co-deliver both drugs, produce synergistic cytotoxicity, inhibit tumor growth, and reduce systemic toxicity.
Aims: Synthesize GEM–stearic acid (GEM-SA) and hyaluronic acid–amino acid–baicalein (HA-AA-BCL) prodrugs. - Prepare and characterize HA-GEM-BCL NLCs and control NLC formulations. - Evaluate cellular uptake, in vitro cytotoxicity, and drug synergy in pancreatic cancer cells. - Assess in vivo antitumor efficacy, biodistribution, and toxicity in a murine pancreatic cancer model.
Delivery system: Platform: Prodrug-based nanostructured lipid carriers (NLCs). - Lipid core: Precirol ATO-5 and olive oil; soybean phosphatidylcholine, Tween 80, and DDAB used as stabilizers/emulsifiers. - Payloads: GEM-SA prodrug and HA-AA-BCL prodrug. - Targeting ligand: Hyaluronic acid (HA, Mw ≈ 10 kDa) on the NLC surface for HA receptor/CD44 targeting. - Key formulation: HA-GEM-BCL NLCs, ~131 nm, PDI ~0.12, zeta potential ~ −25 mV. - Route: Intravenous administration in mice. - Controls: GEM-BCL NLCs without HA, GEM NLCs, BCL NLCs, free drug solutions, saline.
Approach: In vitro cell line: Human pancreatic adenocarcinoma AsPC1 cells. - In vivo model: C57BL/6 mice bearing AsPC1 tumors; treatment started when tumor volume reached 90–110 mm³. - Groups: 8 groups (n = 10 each): saline, GEM solution (10 mg/kg), BCL solution (20 mg/kg), GEM-BCL solution (10/20 mg/kg), GEM NLCs, BCL NLCs, GEM-BCL NLCs, HA-GEM-BCL NLCs. - Dosing: Intravenous injection once every other day for 21 days. - Biodistribution: Drug content measured in tumor, heart, kidney, liver, lung, and spleen at 24 h after administration.
Key methods: ¹H NMR and FT-IR for prodrug synthesis confirmation. - Dynamic light scattering / Zetasizer for particle size, PDI, and zeta potential. - HPLC for entrapment efficiency, drug loading, and in vivo drug quantification. - In vitro release at pH 5.0 and 7.4. - Flow cytometry with coumarin-6 for cellular uptake. - MTT assay for cytotoxicity, IC₅₀, and combination index (CI). - Tumor volume, tumor inhibition rate (TIR), body weight, and tissue biodistribution.
Key results: HA-GEM-BCL NLCs: size 131.4 ± 3.9 nm, PDI 0.12 ± 0.03, zeta potential −25.1 ± 1.9 mV, GEM EE 85.1 ± 2.3%, BCL EE 82.9 ± 2.4%. - NLCs were stable over 1 month; release was faster at pH 5.0 than pH 7.4. - Cellular uptake of HA-GEM-BCL NLCs was significantly higher than other NLCs; >80% uptake at 10 h. - Best in vitro synergy at GEM:BCL = 1:2. HA-GEM-BCL NLCs had IC₅₀ GEM 6.9 ± 0.8 µM, BCL 13.7 ± 1.1 µM, CI₅₀ 0.55. - In vivo, HA-GEM-BCL NLCs produced the strongest tumor growth inhibition among all groups; NLC groups showed less body-weight loss than free drug solutions. - Biodistribution: GEM and BCL accumulated mainly in tumor, lung, and liver after HA-GEM-BCL NLCs, with lower levels in heart and kidney.
Interpretation: HA-GEM-BCL NLCs effectively target HA receptor-overexpressing pancreatic cancer cells, co-deliver GEM and BCL, show synergistic cytotoxicity, and significantly inhibit tumor growth in vivo with reduced systemic toxicity. The authors propose this as a promising targeted nanomedicine platform for pancreatic cancer.
Limitations: Only one pancreatic cancer cell line (AsPC1) and one animal model were used. - Human AsPC1 cells were implanted in immunocompetent C57BL/6 mice, which raises potential immunogenicity/graft-rejection concerns. - No survival study; efficacy was monitored for only 21 days. - No long-term toxicity or repeated-dose safety evaluation. - HA targeting was inferred from uptake/efficacy but not directly validated by CD44 blocking or receptor competition. - No comparison with clinical standard regimens such as gemcitabine/nab-paclitaxel. - No large-animal validation.
Related articles
Biochemical Pharmacology*, Volume 173, 2020, Article 113648 DOI/
7-Ketocholesterol and 7β-Hydroxycholesterol — In Vitro and Animal Models, Biological Activities, and Toxicity-Preventing Molecules
Nature Reviews Drug DiscoveryEngineering Precision Nanoparticles for Drug Delivery
Materials* (MDPI; inferred from format)Generation of Well-Defined Micro/Nanoparticles via Advanced Manufacturing Techniques for Therapeutic Delivery
Let's engineer the next delivery breakthrough together
We co-develop nanocarrier and biosensing programs with pharma, biotech and academic groups — from target selection through GMP supply.